Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Return on Sales: 2014-2025

Historic Return on Sales for Viridian Therapeutics, Inc.\DE (VRDN) over the last 10 years, with Sep 2025 value amounting to -4.27%.

  • Viridian Therapeutics, Inc.\DE's Return on Sales rose 84635.00% to -4.27% in Q3 2025 from the same period last year, while for Sep 2025 it was -4.27%, marking a year-over-year increase of 84635.00%. This contributed to the annual value of -893.87% for FY2024, which is 13676.00% down from last year.
  • Viridian Therapeutics, Inc.\DE's Return on Sales amounted to -4.27% in Q3 2025, which was up 99.52% from -893.42% recorded in Q4 2024.
  • Viridian Therapeutics, Inc.\DE's 5-year Return on Sales high stood at -4.27% for Q3 2025, and its period low was -893.42% during Q4 2024.
  • For the 3-year period, Viridian Therapeutics, Inc.\DE's Return on Sales averaged around -546.43%, with its median value being -757.11% (2023).
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Return on Sales plummeted by 68,382bps in 2023 and then surged by 84,635bps in 2025.
  • Viridian Therapeutics, Inc.\DE's Return on Sales (Quarterly) stood at -26.81% in 2021, then crashed by 4,648bps to -73.29% in 2022, then crashed by 68,382bps to -757.11% in 2023, then crashed by 13,630bps to -893.42% in 2024, then surged by 84,635bps to -4.27% in 2025.
  • Its last three reported values are -4.27% in Q3 2025, -893.42% for Q4 2024, and -850.63% during Q3 2024.